ASCO GU Conference Coverage

Heat Biologics Offers Further Bladder Cancer Treatment Outlook

(Triangle Business Journal) Feb 21, 2017 - After announcing disappointing Phase 2 bladder cancer treatment results in November, Durham’s Heat Biologics presented data from its trial at the Genitourinary Cancers Symposium in Orlando last week, along with company outlook in the space.

read article (free registration required)

In NEJM: Practice-Changing Trial in Urothelial Cancer

(Medscape Medical News) Feb 17, 2017 - For the first time in decades, there is a major advance in the second-line treatment of patients with advanced urothelial carcinoma whose disease has recurred or progressed after initial chemotherapy, according to new trial results published today in the New England Journal of Medicine.

read article (free registration required)

Phase II Study Supports Potential for Genentech’s Tecentriq® (Atezolizumab) Plus Avastin® (Bevacizumab) for People with Locally Advanced or Metastatic Renal Cell Carcinoma

(Genentech) Feb 17, 2017 - Genentech, a member of the Roche Group, today announced encouraging results from the Phase II IMmotion150 study that compared TECENTRIQ® (atezolizumab) plus Avastin® (bevacizumab) and TECENTRIQ monotherapy to sunitinib alone in people with previously untreated, locally advanced or metastatic renal cell carcinoma (mRCC).

read corporate press release

OncoGenex Pharmaceuticals, Inc. Announces Phase 2 Apatorsen Data for Two Clinical Trials Presented at the American Society of Clinical Oncology (ASCO) 2017 Genitourinary Cancers Symposium

(TheStreet) Feb 21, 2017 - Data support continued exploration of Hsp27 inhibition in bladder and prostate cancers.

read article

In Sunny LA, Prostate Cancer Patients Just Walk Away

(Medscape Medical News) Feb 20, 2017 - In "real world" practice, men with prostate cancer are walking away from active surveillance at much higher rates compared with what is seen in prospective trials at academic centers, according to a new study that offers a rare look into the "lost to follow-up" phenomenon in everyday practice.

read article (free registration required)

Clinical Data from Phase 1 Dose-Escalation Study of Single-Agent NKTR-214 in Patients with Renal Cell Carcinoma Presented at the ASCO 2017 Genitourinary Cancers Symposium

(Yahoo! Finance) Feb 18, 2017 - Nectar Therapeutics today announced that positive Phase 1 clinical data for Nektar's lead immuno-oncology agent, NKTR-214, in patients with renal cell carcinoma (RCC) were presented at ASCO GU 2017.

read article

Myriad's Prolaris® Test Significantly Improves the Risk Classification for One Third of Men Diagnosed with Localized Prostate Cancer

(Myriad) Feb 17, 2017 - Myriad Genetics, Inc., a global leader in personalized medicine, today announced new data demonstrating the utility of the Prolaris® test to more accurately classify mortality risk and guide the management of newly diagnosed men with prostate cancer.

read corporate press release

Drug Used to Combat Pain Medication Side Effects May Help with Gastrointestinal Recovery and Shorten Length of Hospital Stay Following Testicular Cancer Surgery

(Rutgers/CINJ) Feb 13, 2017 - Rutgers Cancer Institute of New Jersey investigator presents findings at national meeting.

read press release

2017 Symposium Highlights Notable Research Advances in Genitourinary Cancers

(2017 Genitourinary Cancers Symposium) Feb 15, 2017 - Five studies exploring key issues in the treatment of genitourinary cancers will be presented at the 2017 Genitourinary Cancers Symposium, taking place February 16-18 at Rosen Shingle Creek in Orlando, Florida. These noteworthy abstracts investigate several approaches to the treatment and management of prostate cancer, bladder cancer, and advanced kidney cancer.

read press release

Some Patients Experience Long-Term Tumor Control Even After Stopping Immunotherapy Early

(2017 Genitourinary Cancers Symposium) Feb 13, 2017 - Early findings from a new study appear to challenge the current standard practice for immune checkpoint inhibitor therapy - continuing treatment until cancer worsens.

read press release

Some Stop Immunotherapy, Still Have Controlled Cancer

(Medscape Medical News) Feb 14, 2017 - In a small study of patients with advanced renal cell carcinoma, nearly half had durable responses after discontinuing checkpoint inhibitors because of toxicities.

read article (free registration required)

In Advanced Kidney Cancer, Antibiotic Use Lowers Efficacy of Immunotherapy

(2017 Genitourinary Cancers Symposium) Feb 13, 2017 - A new retrospective analysis suggests that immunotherapy may be less effective in patients who receive antibiotics less than a month before starting treatment.

read press release

Antibiotics May Compromise Immunotherapy Efficacy in Kidney Cancer

(CureToday.com) Feb 14, 2017 - Patients with metastatic kidney cancer may see a decreased efficacy of their immunotherapy regimen if they recently took antibiotics.

read article

Blood Test Uncovers Potential New Treatment Targets in Advanced Prostate Cancer

(2017 Genitourinary Cancers Symposium) Feb 13, 2017 - Analysis of free-floating cancer DNA from blood samples has yielded leads for new prostate cancer treatment targets.

read press release

Blood Test Instead of Biopsy for Metastatic Prostate Cancer

(Medscape Medical News) February 14, 2017 - Cell-free ctDNA provided comprehensive information about genetic changes in the tumor and may be a viable alternative to tissue biopsy.

read article (free registration required)

Taking a High-Priced Cancer Drug with a Low-Fat Meal Can Cut Cost by 75%

(University of Chicago Medicine/Science Life) Feb 14, 2017 - Taking one-fourth the standard dose of a widely used drug for prostate cancer with a low-fat breakfast can be as effective - and four times less expensive - as taking the standard dose as recommended: on an empty stomach.

read article